Evidence map›Paper›PMID 40759950›Full record

ReviewJournal of cheminformatics2025

Generative artificial intelligence based models optimization towards molecule design enhancement.

Tarek Khater, Sara Awni Alkhatib, Aamna AlShehhi, Charalampos Pitsalidis, Anna Maria Pappa, Son Tung Ngo, Vincent Chan, Vi Khanh Truong

Abstract readReview
In one paragraph

Review in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tarek KhaterDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Sara Awni AlkhatibDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Aamna AlShehhiDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Charalampos PitsalidisDepartment of Physics, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Anna Maria PappaDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates.
Son Tung NgoLaboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
Vincent ChanDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates. Vincent.chan@ku.ae.ac.
Vi Khanh TruongDepartment of Biomedical Engineering and Biotechnology, Khalifa University, P.O. Box 127788, Abu Dhabi, United Arab Emirates. Vikhanh.truong@ku.ac.ae.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generative artificial intelligence (GenAI) models have emerged as a transformative tool for addressing the complex challenges of drug discovery, enabling the design of structurally diverse, chemically valid, and functionally relevant molecules. Despite significant advancements, the rapid expansion of GenAI applications still faces challenges related to prediction accuracy, molecular validity, and optimization for drug-like properties. This review provides a comprehensive analysis of recent techniques and strategies aimed at enhancing the performance of GenAI models in molecular design. We explore key generative architectures, including variational autoencoders, generative adversarial networks, and transformer-based models, highlighting their unique contributions to drug discovery. Additionally, we discuss critical advancements such as reinforcement learning, multi-objective optimization, and the integration of domain-specific chemical knowledge, which collectively enhance molecular validity, novelty, and drug-likeness. Also, the review examines persistent challenges, including data quality limitations, model interpretability, and the need for improved objective functions, while offering insights into future research directions. By mapping the evolving landscape of GenAI-driven molecular design and providing strategic guidance for overcoming existing limitations, this review serves as an essential resource for researchers leveraging GenAI in drug discovery.

Indexed as

Chemical informaticsDrug discoveryGenerative AIMolecular designOptimizationReinforcement learning

Identifiers

PMID40759950
PMCPMC12323263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.